Highest-materiality recent filing
Incannex granted US patent covering IHL-42X for obstructive sleep apnea through 2040
USPTO granted patent for IHL-42X composition and methods for OSA; baseline expiry 9 July 2040.
Incannex receives A$6M R&D tax refund; expects another A$5.1M in 2026
Received A$6,039,162 under Australian Government's R&D Tax Incentive Program for FY25.
Incannex initiates research coverage by Alliance Global Partners with BUY rating, $18 PT
Alliance Global Partners (AGP) initiates coverage with BUY rating and $18.00 price target as of June 8, 2026.
Incannex commences DReAMzz study of IHL-42X for obstructive sleep apnea
All 14 clinical trial sites identified; site contracting underway; import/export permits secured.
Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X for Obstructive Sleep Apnea
Awarded 'Best New Technology Solution for Drug Development' in 10th annual MedTech Breakthrough Awards program.
White House Executive Order (April 18, 2026) directs FDA to prioritize psychedelic compounds with Breakthrough Therapy designations and creates Right to Try pathways.
Incannex reactivates share repurchase program, citing undervaluation and $75M cash
Board reinitiated buyback after inactivity; purchases executed over past two trading days.
Incannex partners with AASM Foundation, sponsors junior investigator sleep apnea grant
Partnership with AASM Foundation Corporate Recognition Program to support sleep apnea research.
Incannex reports ~$75M cash, no debt; advances IHL-42X sleep apnea program
Cash position ~$75M, no debt; market cap ~$46M, resulting in negative enterprise value.
Incannex regains Nasdaq minimum bid price compliance; listing overhang removed
Nasdaq confirmed compliance after IXHL closed at ≥$1.00 for 11 consecutive business days through March 13, 2026.
Incannex terminates $108.4M ATM sales agreement; announces enhanced Phase 2 dose-optimisation study
Mutually terminated Sales Agreement with Curvature Securities and A.G.P., effective March 11, 2026.
Offering consists of 2,000,000 shares (or equivalents) and 2,000,000 common warrants; combined price $5.00 per share and accompanying warrant.
Incannex Healthcare files for 1-for-30 reverse stock split to regain Nasdaq compliance
Reverse split at 1-for-30 effective 4:01 p.m. ET Feb 26, 2026; post-split trading begins Feb 27 under same ticker IXHL.
Incannex Healthcare Appoints Three New Members to Clinical Advisory Board for PSX-001 Program
Appointed Murray B. Stein, MD, MPH (UCSD); Andrew Cutler, MD (SUNY Upstate); and Amir Kalali, MD to Clinical Advisory Board.
Incannex Healthcare forms Clinical Advisory Board for PSX-001 anxiety program
Clinical Advisory Board (CAB) established to support PSX-001 development for generalized anxiety disorder.
Incannex Healthcare annual meeting elects directors and ratifies auditor
Quorum of 119,550,295 shares (34.38%) present at Jan 15, 2026 annual meeting.
Incannex wins R&D award for obstructive sleep apnea drug IHL-42X
Recognized in Respiratory Disorders category of 2025 Clinical Trials Arena Excellence Awards.
Incannex reports >$70M cash, two positive Phase 2 readouts, FDA Fast Track; outlines 2026 outlook
Cash and cash equivalents >$70M, providing operating runway into 2027.
No quorum at Dec 18, 2025 annual meeting due to Auditor Ratification Proposal being misclassified as non-routine by transfer agent.
FDA grants Fast Track designation to Incannex's IHL-42X for obstructive sleep apnea
FDA Fast Track designation for Incannex's IHL-42X for obstructive sleep apnea (OSA).
Incannex updates on Phase 2 results for IHL-42X and PSX-001; ATM shares unchanged since Aug 2025
IHL-42X Phase 2 OSA trial showed up to 83% reduction in AHI; 57.6% of participants reported improvement (78.6% low dose).
Incannex Healthcare gets Nasdaq bid price compliance extension to April 20, 2026
Received second 180-day grace period from Nasdaq until April 20, 2026 to regain $1 minimum bid price.
Incannex gets 180-day Nasdaq extension to April 20, 2026 for bid price compliance
Nasdaq granted Incannex until April 20, 2026 to maintain $1.00 closing bid for 10 consecutive days.
Incannex reports positive Phase 2 results for PSX-001 in Generalized Anxiety Disorder
Psi-GAD (PSX-001) achieved a 12.8-point HAM-A reduction vs. 3.6 for placebo (p<0.0001) over 11 weeks.
Incannex Healthcare authorizes $20M share repurchase program
Board approved repurchase of up to $20M of common stock via open market or negotiated transactions.
Low- and high-dose IHL-42X achieved statistically significant reduction in AHI vs placebo (p<0.05); max AHI reduction 83% in high-dose group.
Incannex states no plans to fully utilise ATM near term; cash ~$50M
Cash balance ~US$50M; no plan to fully utilise ATM in near term; sold only 1.97% of volume on Jul 30.
IHL-42X reduced AHI up to 83% (high-dose) and 79% (low-dose) from baseline; 41.2% of high-dose patients achieved >30% reduction.
Incannex appoints Dr. Gamaldo to OSA advisory board; Phase 2 data due next week
Dr. Charlene E. Gamaldo (Johns Hopkins professor) joins IHL-42X Obstructive Sleep Apnea Clinical Advisory Board.
Incannex Healthcare increases ATM capacity by $100 million for financial flexibility
Filed prospectus supplement to increase ATM offering capacity by up to $100 million in common shares.
Incannex appoints Dr. Kirsch to OSA board; Phase 2 data due July 2025
Appointed Douglas B. Kirsch, M.D., FAAN, FAASM to IHL-42X Obstructive Sleep Apnea Clinical Advisory Board.
Database lock achieved June 16, 2025, on schedule; final statistical analysis begins.
Incannex Healthcare forms 50:50 JV with Mind Medicine Australia for psychedelic therapy clinic
JV creates 'Mind Medicine Australia Clinics' to operate a clinic in Melbourne.
Voluntary transfer from Nasdaq Global Market to Nasdaq Capital Market announced June 11, 2025.
Incannex cancels all Series A Warrants, eliminating 347.2M shares of potential dilution
Cancelled remaining 172M Series A Warrants for $12.2M via ATM facility; combined with earlier tranche removes 347.2M shares.
Incannex adds four OSA experts to IHL-42X advisory board; Phase 2 data July 2025
Appointed Scott Sands, Ali Azarbarzin, Lora McGill, and Nancy Collop to the IHL-42X Clinical Advisory Board.
Incannex Healthcare advances IHL-42X RePOSA trial to Phase 3 after FDA clearance
FDA cleared Phase 3 protocol for IHL-42X under IND; trial for obstructive sleep apnea (OSA) with no approved oral therapy.
Authorized common shares increased from 100M to 800M; shareholders approved at May 27 special meeting.
Incannex cancels 172M Series A warrants, eliminating up to 347.2M shares from dilution
Agreement to cancel remaining 172M Series A warrants; cancellation payment up to $12.2M.
Incannex Healthcare increases ATM offering capacity by up to $2.5M after $16.8M already sold
Filed prospectus supplement on May 20, 2025, raising maximum shares under ATM to $2,514,214.
Incannex cancels 50.4% of Series A Warrants, reduces potential dilution from 175M shares
Raised $16.7M gross via ATM; used $12.5M to cancel up to 5,841,038 Series A Warrants (50.4%).
Incannex enters agreements to reduce up to 50.4% of Series A warrant shares
First ~$12.5M net proceeds from ATM to cancel up to 5,833,333 underlying shares (adjustable to 175M).
Incannex Q3 FY2025 net loss $3.97M, cash $6.71M, IHL-42X Phase 2 dosing done
Net loss of $3.97M for quarter ended March 31, 2025, vs $6.03M same quarter last year.
Up to $12.5M in net proceeds from ATM offering to be paid as Warrant Cancellation Payment to Series A holders.
Incannex completes Phase 2 dosing of IHL-42X for OSA; topline data expected July 2025
Completed patient dosing in Phase 2 portion of RePOSA study on May 8, 2025; end-of-study follow-up by May 17, 2025.
Incannex receives Nasdaq bid price deficiency notice; cure period until Oct 20, 2025
Closing bid price of IXHL common stock below $1.00 for 30 consecutive trading days.
Incannex Healthcare enters ATM sales agreement for up to $16.8M common stock offering
Sales agreement with A.G.P./Alliance Global Partners; 3.0% commission on gross proceeds.
Completed enrollment of >120 patients across 11 U.S. sites in Phase 2 dose-finding portion of RePOSA Phase 2/3 study of IHL-42X for OSA.
Incannex repays $3.85M convertible debenture, terminates Arena financing agreements
Repaid outstanding 10% OID Senior Secured Convertible Debenture with $3,851,111 cash payment on March 13, 2025.
Incannex prices $12.5M private placement at $1.08/share to fund OSA trial
Gross proceeds $12.5M from 11.57M shares at $1.08 plus Series A warrants at $2.16.
Effective October 21, 2024 (the “Effective Date”), Incannex Healthcare Inc. (the “Company”) entered into an employment agreement (the “Employment Agreement”) with Luigi M. Barbato, M.D., to serve as the Company’s Chief Medical Officer.
Madhukar Bhalla, Chief Financial Officer and Secretary of Incannex Healthcare Inc. (the “Company”), recently notified the Company of his decision to resign from his positions effective as of February 28, 2024.
The Company’s Board of Directors has appointed Joseph Swan, the current Treasurer and Controller of the Company, as its Chief Financial Officer and Secretary effective as of February 29, 2024.
Max materiality 1.00 · Median 0.65 · Most common event other_material